Find and Pitch Jounalists, Get Your Story Covered

Tags: Deal Evergreen Deals Entertainment Mobile Commerce 2022

	Profile	Recent Articles on Subject
1	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Is New Standard of Care for High-Risk Early-Stage TNBC - 2 months ago Advancements in HER2+ Breast Cancer Treatment: Insights From the HER2CLIMB-02 Trial - 9 months ago Use of Recurrence Score Combined With Clinical, Genetic Factors Improves Prognostic Ability in HR+/ HER2– Early Breast Cancer - 11 months ago Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard of Care Regimen for Previously Untreated CLL - 12 months ago
2	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer - 2 months ago Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC - 4 months ago Most Cancer Drugs Granted Accelerated Approval Fail Confirmatory Trials - 8 months ago Chemotherapy/ICI Combos Falter as Second-Line Treatment for Gastric Cancer - 8 months ago Rucaparib Maintenance Boosts PFS in Metastatic, Recurrent Endometrial Cancer - 8 months ago Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLC - 9 months ago Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer - 12 months ago Novel Therapy Reduced Transfusion Dependence in Lower-Risk MDS - 12 months ago First Gene Therapy for Non-Muscle-Invasive Bladder Cancer Offers Durable Response - 12 months ago RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer - about 1 year ago Maintenance Selinexor May Boost PFS in TP53 Wild-Type Advanced Endometrial Cancer - about 1 year ago Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers - about 1 year ago RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC - about 1 year ago Multi-Agent Treatment Offers Hope in Advanced or Recurrent Endometrial Cancer - about 1 year ago Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer - about 1 year ago
3	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Incyte’s checkpoint inhibitor staves off disease progression in anal cancer trial - 2 months ago STAT+: Results on Novartis prostate cancer therapy could expand its use - about 1 year ago
4	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	'Very Clear Signal' That Survival Improved With Addition of Durvalumab in SCLC - 5 months ago Adding Tucatinib to T-DM1 Shows PFS Benefit in HER2-Positive Breast Cancer - 11 months ago KEYNOTE-A18 Data Are 'Practice-Changing' for Cervical Cancer - 12 months ago New Data on CD40 Ligand Inhibitor for Relapsing MS - about 1 year ago
5	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Durvalumab Plus Chemotherapy to Treat Endometrial Cancer - 5 months ago FDA Grants Orphan Drug Designation for CAN-2409 to Treat Pancreatic Cancer - 8 months ago Durvalumab Shows Improvements in Overall Survival, Progression-Free Survival for Small Cell Lung Cancer - 8 months ago Adagrasib Meets Primary Endpoint Among Individuals with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC - 8 months ago Osimertinib With Chemotherapy Could Aid Overall Survival for NSCLC - 8 months ago Phase 3 Trial of Pembrolizumab with Olaparib Did Not Meet Endpoints Among Individuals with NSCLC - 8 months ago Phase 3 EVOKE-01 Study in Metastatic NSCLC Falls Short of Primary Endpoint - 9 months ago FDA Grants Priority Review for Pembrolizumab in Progressive Cervical Cancer - about 1 year ago
6	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical - 6 months ago
7	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Dostarlimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in Endometrial Cancer - 8 months ago Pembrolizumab, Chemoradiotherapy Meet Overall Survival Endpoint for Cervical Cancer - 8 months ago FDA Grants Breakthrough Therapy Designation to Novel Drug for Progressive Pulmonary Fibrosis - about 1 year ago Datopotamab Deruxtecan Demonstrates Improvement in Progression-Free Survival in HR+, HER2- Breast Cancer - about 1 year ago
8	Pharmaceutical Executive Editorial Staff Pharmaceutical Executive Pharma Executive Magazine. London & New Jersey PharmaceuticalsHealthcare	GSK's Jemperli Plus Zejula Produces Significant Survival Improvement in Endometrial Cancer - 11 months ago FDA Grants Orphan Drug Designation to Novel Treatment for Leptomeningeal Metastases in Breast Cancer - about 1 year ago
9	Wayne Kuznar MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Add-On Inavolisib Ups PFS in PIK3CA-Mutated Breast Cancer - 12 months ago Maintenance Pembrolizumab-Olaparib Fails to Boost Survival in TNBC - 12 months ago
10	Erin Hunter, Assistant Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	Golidocitinib Demonstrates Significant Survival Benefits For Patients with Peripheral T-cell Lymphoma - 12 months ago FDA Approves First Therapy for Rare Invasive Tumor Type With High Risk of Recurrence - 12 months ago Nivolumab Combination Regimen Improved Survival of Patients with Bladder Cancer By A Third Compared to Chemotherapy Alone - about 1 year ago Novel Oral Medication Reduces Risk of Death by 76% in Patients With ALK-Positive Lung Cancer - about 1 year ago

Journalists covering progression-free survival